Tecfidera denied by insurance? Appeal and win.
A denial of Tecfidera is rarely the final word. It is the start of a process, and these denials are usually procedural rather than a judgment that the drug is wrong for you. Most are tied to step therapy through a preferred oral DMT, to a generic dimethyl fumarate substitution, or to prior authorization paperwork that does not yet show your MS diagnosis and prior treatment history. Documenting the diagnosis, the agents you have already tried or cannot use, and your neurologist's rationale is usually what flips the decision.
Reviewed by the Apellica Appeals Team · Updated June 2026
Carrier names and logos are trademarks of their respective owners. Apellica is independent and not affiliated with any insurance carrier or carrier's appeal program.
Tecfidera (dimethyl fumarate) is FDA approved for adults with relapsing forms of multiple sclerosis. This covers clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It is an oral disease-modifying therapy taken twice daily, used to reduce the rate of relapses, slow the development of new brain lesions, and delay the progression of disability.
Why Tecfidera gets denied
- Step therapy: the plan requires you to try and fail one or more preferred oral DMTs (such as a generic dimethyl fumarate, diroximel fumarate, or another formulary first-line agent) before it will cover brand Tecfidera.
- Non-formulary or generic substitution: many plans now cover generic dimethyl fumarate on a preferred tier and exclude or non-prefer the Tecfidera brand, triggering a denial unless brand is justified.
- Prior authorization criteria not documented: the submission does not clearly show the relapsing MS diagnosis, ICD-10 code, or that the drug was prescribed by or in consultation with a neurologist.
- Missing or incomplete monitoring documentation: the plan expects a baseline CBC with lymphocyte count and an ongoing monitoring plan, and denies when these are not on file.
What a winning appeal includes
- A clear diagnosis statement with the ICD-10 code (G35, multiple sclerosis) and confirmation that the prescriber is a neurologist or is consulting one, matching the plan's prior authorization criteria.
- A documented record of prior DMTs tried, with dates and the reason each was stopped (inadequate response, relapse, intolerance, or contraindication), to satisfy or override step therapy.
- A letter of medical necessity that maps your clinical situation point by point to the plan's own published coverage criteria for dimethyl fumarate.
- Baseline and follow-up labs, specifically a CBC with lymphocyte count, plus the monitoring plan, since the label calls for CBC before starting, at 6 months, and every 6 to 12 months thereafter.
How we approach the appeal
Identify which lane the denial sits in, because the appeal differs. If the issue is tier or formulary status (for example, brand Tecfidera versus generic dimethyl fumarate), file a formulary or tier exception and have your neurologist document why the specific product is medically necessary. If the denial is a prior authorization or step therapy decision, appeal on medical necessity and quote the plan's own criteria back to it, attaching the MS diagnosis, prior therapy history, neurologist involvement, and CBC monitoring records so each stated requirement is visibly met. If the internal appeal is upheld, request an independent external review, where a neutral physician reviewer evaluates whether the plan applied its criteria correctly.
Tecfidera appeal letter template
Copy this Tecfidera appeal letter, fill in the brackets, and send it within your deadline. It is built on what overturns Oral fumarate disease-modifying therapy (Nrf2 pathway activator) denials.
[Date] [Your name] · Member ID [ID] · Rx claim # [#] [Insurer or PBM] - Appeals Department Re: Appeal of Tecfidera denial I am appealing the denial of Tecfidera (dimethyl fumarate). I request that the denial be overturned and Tecfidera approved. 1. The denial. [Insurer] denied Tecfidera stating, verbatim: "[paste the exact denial reason from your letter]." 2. Medical necessity. Tecfidera is medically necessary for my condition. Identify which lane the denial sits in, because the appeal differs. If the issue is tier or formulary status (for example, brand Tecfidera versus generic dimethyl fumarate), file a formulary or tier exception and have your neurologist document why the specific product is medically necessary. If the denial is a prior authorization or step therapy decision, appeal on medical necessity and quote the plan's own criteria back to it, attaching the MS diagnosis, prior therapy history, neurologist involvement, and CBC monitoring records so each stated requirement is visibly met. If the internal appeal is upheld, request an independent external review, where a neutral physician reviewer evaluates whether the plan applied its criteria correctly. 3. Step-therapy or formulary exception (if that was the reason): I have tried and failed [preferred drug(s)], with pharmacy records attached, or the preferred alternative is contraindicated because [reason]. I request a formulary or step-therapy exception. 4. My request. Approve Tecfidera within the timeframe required by law. If the denial is upheld, please provide the specific criteria used, the reviewing clinician's credentials, and external-review instructions. Attached: prescriber letter of medical necessity, pharmacy and prior-trial records, and supporting clinical notes. Sincerely, [Your name]
Want it built and filed for you? Use the free generator, or have Apellica do it.
Internal appeals: 30 days pre-service, 60 days post-service, 72 hours urgent. File within 180 days of the denial.
$0 upfront. We assess fit first, then build and file the appeal for you.
- · The denial letter and your Explanation of Benefits (EOB)
- · Insurance ID, plan name, and the claim or prior-authorization number
- · Diagnosis with ICD-10 code and the prescriber's clinical notes
- · A record of treatments already tried and how they worked
Appealing a Tecfidera denial by insurer
The path depends on who manages your benefit. The most common:
Coverage runs through the pharmacy benefit. Appeal the coverage determination and, when the drug is non-formulary, file a formulary or tier exception with a provider attestation that covered alternatives are unsuitable.
Publishes detailed prior-authorization criteria. A denial usually means a criterion was not documented. Appeal through a coverage review, with a formulary exception for excluded drugs.
Administers many UnitedHealthcare and employer plans. Appeals and exceptions follow the plan's published PA criteria; expedited review exists for urgent cases.
Internal appeal first, then independent external review. Pre-service decisions are generally made within 30 days, urgent within 72 hours.
Internal appeals and external review; pharmacy denials often route through OptumRx criteria.
Independent state plans, so criteria vary. Match the appeal to your specific BCBS plan, internal appeal first, then external review.
Frequently asked questions
My plan wants me to try generic dimethyl fumarate first. Can I still get brand Tecfidera covered?
Often yes, but you need a clinical reason on record. If you have already used generic dimethyl fumarate and had a worse response, a tolerability problem, or a documented reaction, your neurologist can request brand Tecfidera through a formulary exception and explain why the specific product is medically necessary. Without that documented rationale, most plans will default to the generic.
Why does my insurer keep asking for bloodwork before approving Tecfidera?
The FDA label directs prescribers to obtain a CBC with lymphocyte count before starting Tecfidera, again at 6 months, and then every 6 to 12 months. This is tied to monitoring for low lymphocyte counts and the rare risk of PML. Including your baseline labs and your ongoing monitoring plan in the prior authorization usually clears this requirement and removes a common reason for denial.
My appeal was denied internally. Is there anything left to do?
Yes. After an internal appeal is upheld, you can request an independent external review, where a physician who does not work for your insurer evaluates the decision. For a relapsing MS therapy like Tecfidera, a complete file with the G35 diagnosis, prior DMT history, neurologist rationale, and monitoring labs gives the external reviewer what they need to overturn a denial that did not properly apply the plan's own criteria.
Tecfidera denied? We fight it for you.
$0 upfront. Two-minute intake. We confirm fit and reply within one business day with the right path for your situation.
Start Your AppealThis page provides general information about appeal strategy. It is not legal or medical advice. Apellica is not a law firm. Outcomes depend on documentation, plan terms, and timing.